Price Controls Are Bad Medicine
Published in the Star-Ledger Editorial Page BY BOB FRANKS Bridgewater, NJ, January 12, 2007 —Our nation’s new Congress, as part of its much-heralded “first 100 hours,” is promising to overhaul the Medicare Part D prescription benefit program. That vote could come as early as today.
HINJ Economic Impact Report: Strong Medicine: New Jersey and the Pharmaceutical and Medical Technology Industry
2005 Economic Impact of HINJ Members Totals A Record $27 Billion Bridgewater, NJ, June 19, 2006 — Reversing a two-year trend, New Jersey’s pharmaceutical and medical technology industry reported strong economic activity and an economic impact of $27 billion on the state’s economy in 2005, according to a study released today in the State House […]
Economic Impact Report: HINJ Members Bolster State’s R&D Efforts, Industry Investments Up $1 Billion
NJ’s Pharmaceutical & Medical Technology Industry Report Finds Healthy Drug, Device Pipeline R&D spending of $4.7 billion Payroll Impacts of over $6.6 billion Average base salary is $110,017 Capital Construction Projects of $1.35 billion Industry produced 151,000 jobs –60,000 direct + 91, 000 spin-off jobs Charitable Contributions totaled $133 million $617.6 M in sales tax […]
State’s Key Economic Incentive Programs Foster High Tech Jobs
By The Honorable Bob Franks, President, HealthCare Institute of New Jersey Hillside, NJ, May 24, 2005 —The life sciences have clearly become the leadership industry of New Jersey. Our rank as the state with the most scientists and engineers per square mile has helped cement this status. And, you merely need to look at the […]
New Jersey’s Life Science Cluster Anchor to the Medicine Chest of the World
Hillside, NJ, August 5, 2004 — The pharmaceutical and medical technology industry has long been an economic engine in New Jersey, with many companies arriving here more than a century ago. Now, a groundbreaking study conducted by renowned Harvard Professor Michael E. Porter underscores the importance of this industry to the state’s “life sciences cluster.”
BD Chairman Edward J. Ludwig to Lead HealthCare Institute of New Jersey
Hillside, NJ, July 19, 2004 — Edward J. Ludwig, Chairman, President and Chief Executive Officer of BD (Becton, Dickinson and Company) (NYSE:BDX), has recently been elected Chairman of the HealthCare Institute of New Jersey (HINJ). Mr. Ludwig will serve a two-year term and is the first executive from a medical technology company to lead the […]
HINJ Releases 2004 Economic Impact Report: Impact of HINJ Members Climbs to $23.8 Billion
NJ’s Pharmaceutical & Medical Technology Industry Continues to Drive State’s Economy Industry created 156,000 jobs – 63,000 direct + 93, 000 spin-off jobs Average base salary is $85, 423 Payroll Impacts of $6 billion Charitable Contributions totaled $155 million $213.1 M in sales tax and income tax impacts on NJ Hillside, NJ, April 27, 2004 […]
The State of Our Life Sciences Industry
By The Honorable Bob Franks, President, HealthCare Institute of New Jersey Hillside, NJ, February 2, 2004 —Nowhere on earth is there a more important place for the pharmaceutical and medical technology industry than our own state of New Jersey.
Why America Needs a Medicare Prescription Drug Benefit
By The Honorable Bob Franks, President, HealthCare Institute of New Jersey Hillside, NJ, June 16, 2003 — In a rare display of bipartisan resolve, Congress may finally be able to pass a landmark Medicare reform bill in the next few weeks, giving seniors a much needed prescription-drug benefit.
HINJ Interview with Congressman Rodney Frelinghuysen
Hillside, NJ, May 1, 2003 — The following is an interview between HINJ President Bob Franks and Congressman Rodney Frelinghuysen, a Republican who represents New Jersey’s 11th Congressional District.